crb-601
corbus pharmaceuticals
['crb-601']
proud of my colleagues at for this pre-clinical data they just presented at aacr23 on crb-601. the potential clinical applications of inhibiting the integrin avb8 to control tgf-beta are significant. 
I'm the CEO of @CorbusPharma ($CRBP). I'm passionate about inflammatory/fibrotic/metabolic diseases and cancer. These opinions are my own.